CCA
AMED

Catalyst Capital Advisors’s Amedisys AMED Stock Holding History

Catalyst Capital Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,000
Closed -$380K – 547
2015
Q3 		$380K Buy
+10,000
New +$422K 0.05% 219

Other funds holding AMED

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Catalyst Capital Advisors's AMED Position: Q4 2015 in Review

Catalyst Capital Advisors sold out of Amedisys (AMED) in Q4 2015, closing a stake of 10,000 shares — an estimated $380K sold.

Catalyst Capital Advisors first reported a position in AMED in Q3 2015 and held it in 1 quarter. The position peaked at $380K in Q3 2015. 165 funds tracked by Wall St. Rank hold AMED as of Q4 2015.

  • Catalyst Capital Advisors reported no remaining Amedisys position as of Q4 2015 after selling out during the quarter.
  • Catalyst Capital Advisors sold 10,000 Amedisys shares in Q4 2015, an estimated $380K.
  • Catalyst Capital Advisors first reported a position in Amedisys in Q3 2015 and held it in 1 quarter.
  • Catalyst Capital Advisors's Amedisys position peaked at $380K in Q3 2015.
  • 165 funds tracked by Wall St. Rank held Amedisys as of Q4 2015.

Based on Catalyst Capital Advisors's 13F filing for Q4 2015, filed 10 Feb 2016.